Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to demonstrate the safety and efficacy of Sirolimus 0.2% topical gel for patients with Acanthosis Nigricans
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Men and women ages 18+.
• Clinical diagnosis of acanthosis nigricans.
• Available and willing to comply with study instructions and attend all study visits.
• Able and willing to provide written and verbal informed consent.
Locations
United States
New York
New York Harbor VA Brooklyn Campus
RECRUITING
Brooklyn
Contact Information
Primary
Kayla Zafar, BA
kayla.zafar@va.gov
718-836-6600
Time Frame
Start Date: 2025-03-01
Estimated Completion Date: 2025-07-18
Participants
Target number of participants: 5
Treatments
Experimental: Patients with Acanthosis Nigricans
Patients with the diagnosis of acanthosis nigricans
Related Therapeutic Areas
Sponsors
Collaborators: Nobelpharma
Leads: Narrows Institute for Biomedical Research